AN2 Therapeutics, Inc.
ANTX
$1.25
-$0.04-3.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -7.52M | -12.75M | -14.44M | -16.62M | -16.90M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.21M | 1.17M | 1.38M | 1.29M | 926.00K |
| Change in Net Operating Assets | 1.04M | -431.00K | -1.33M | -2.27M | -1.10M |
| Cash from Operations | -5.27M | -12.01M | -14.38M | -17.59M | -17.07M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6.88M | 18.72M | 16.46M | 26.29M | 420.00K |
| Cash from Investing | -6.88M | 18.72M | 16.46M | 26.29M | 420.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 23.00K | 0.00 | 349.00K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -321.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.00 | 23.00K | 0.00 | 349.00K | -321.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -12.15M | 6.74M | 2.08M | 9.05M | -16.97M |